High levels of HER-2/neu or ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma-derived oncogene homolog) expression have been associated with increased disease recurrence in breast cancer, but show a better response to trastuzumab.(10). This evidence concerns the gene ERBB2 and breast carcinoma.